← All Procept Biorobotics CORP filings

Procept Biorobotics CORP 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
PRCT
Procept Biorobotics CORP
10-K: PROCEPT BioRobotics Reports Strong 2025 Revenue Growth
PROCEPT BioRobotics Corporation announced significant revenue growth in its 2025 annual report, driven by increased adoption and utilization of its robotic systems for BPH treatment, despite continued net losses.
NASDAQ
PRCT
Procept Biorobotics CORP
10-K/A: PROCEPT BioRobotics Files Amendment to 10-K to Include Insider Trading Policy
PROCEPT BioRobotics Corporation files an amendment to its annual report to include its Insider Trading Compliance Policy and Procedures, which was inadvertently omitted from the original filing.
NASDAQ
PRCT
Procept Biorobotics CORP
10-K: Procept BioRobotics Reports Strong Revenue Growth in 2024, Narrows Net Loss
Procept BioRobotics' 2024 10-K filing reveals significant revenue growth driven by increased adoption of their Aquablation therapy, alongside a reduction in net losses.
NASDAQ
PRCT
Procept Biorobotics CORP
10-K: Procept Biorobotics Reports Fiscal Year 2023 Results, Revenue Jumps 82%
Procept Biorobotics reports significant revenue growth for fiscal year 2023, driven by increased adoption of its Aquablation therapy.